Synthesis and Anticancer Activities of Amide-Bridged Coumarin–Quinazolinone Hybrid Compounds
| dc.contributor.author | Çalişkan N. | |
| dc.contributor.author | Menteşe E. | |
| dc.contributor.author | Yilmaz F. | |
| dc.contributor.author | Ilhan M.S. | |
| dc.date.accessioned | 2025-04-10T11:02:25Z | |
| dc.date.available | 2025-04-10T11:02:25Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Abstract: Some novel 3-aminoquinazolin-4(3H)-one derivatives were synthesized by the reaction of 2-aminobenzhydrazide and corresponding iminoester hydrochlorides and then reacted with coumarin-3-carbonyl chloride to obtain novel coumarin–quinazolinone hybrids. The synthesized hybrid compounds were screened for their anticancer activity against various human cancer and normal cell lines. N-{2-[(4-Bromo- and N-{2-[(3-bromo-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides exhibited the highest cytotoxic effect on the PC-3 prostate cancer cell line: IC50 35.3 ± 0.6 and 36.8 ± 0.8 µg/L, respectively. N-{2-[(4-Fluoro-, N-{2-[(4-bromo-, and N-{2-[(3,4-dichloro-phenyl)methyl]-4-oxoquinazolin-3(4H)-yl}-2-oxo-2H-1-benzopyran-3-carboxamides showed the highest activity against the MCF-7 breast cancer cell line: IC50 48.5 ± 0.4, 44.8 ± 0.4 and 46.1 ± 0.5 µg/L, respectively. © Pleiades Publishing, Ltd. 2024. | |
| dc.identifier.DOI-ID | 10.1134/S1070428024050142 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/44045 | |
| dc.publisher | Pleiades Publishing | |
| dc.title | Synthesis and Anticancer Activities of Amide-Bridged Coumarin–Quinazolinone Hybrid Compounds | |
| dc.type | Article |